Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder

Roger S McIntyre, Philip Gorwood, Michael E Thase, Charlie Liss, Dhaval Desai, Ji Chen, Michael Bauer, Roger S McIntyre, Philip Gorwood, Michael E Thase, Charlie Liss, Dhaval Desai, Ji Chen, Michael Bauer

Abstract

The aim of this post-hoc analysis was to determine whether early symptom improvement with extended release quetiapine (quetiapine XR) may predict treatment outcome in patients with major depressive disorder. Data were from 6, double-blind, placebo-controlled studies of quetiapine XR (2 fixed-dose and 2 flexible-dose monotherapy and 2 adjunct studies) in adult patients with major depressive disorder. Montgomery-Åsberg Depression Rating Scale (MADRS) and Clinical Global Impression-Severity Score (CGI-S) were assessed at baseline, weeks 2, 4, and 6. Hamilton Rating Scale for Depression (HAM-D) was assessed at baseline and week 6. The MADRS improvement at week 2 (15%, 20%, 25%, 30%) was used to predict response and remission, based on MADRS (50% improvement; total score ≤ 12) or HAM-D (50% improvement; total score ≤ 7). The CGI-S improvement (1 point) at week 2 was used to predict final outcome (CGI-S score ≤ 2). The predictive value for early improvement with quetiapine XR was found to be "very strong" (Yule's Q coefficient, a combined measure of sensitivity and specificity) using 30% MADRS improvement as the threshold. This was relatively comparable for response and remission and for fixed-dose, flexible-dose, and adjunct studies. This was also observed for placebo. Exceptions were: adjunct studies (where predictivity was lower for ongoing antidepressant/placebo), and for remission (predictivity for remission appeared lower than for response with placebo). In conclusion, outcome at week 6 with quetiapine XR for a major depressive episode could be predicted by 30% improvement after 2 weeks, a finding that could give doctors confidence to continue treatment and may facilitate adherence in patients.

Trial registration: ClinicalTrials.gov NCT00320268 NCT00321490 NCT00326105 NCT00326144 NCT00351169 NCT00351910.

Figures

FIGURE 1
FIGURE 1
Predictive value for treatment response (≥50% reduction in MADRS total score) or remission (MADRS total score ≤ 12) to quetiapine XR, according to the level of improvement at week 2 (% reduction in MADRS total score): fixed dose, flexible dose, or as an adjunctive treatment in MDD.

References

    1. Pae CU, Wang SM, Lee SY, et al. Early switch strategy in patients with major depressive disorder. Expert Rev Neurother. 2012; 12: 1185– 1188.
    1. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006; 163: 28– 40.
    1. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011; 71: 43– 64.
    1. Kudlow PA, Cha DS, McIntyre RS. Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement. Can J Psychiatry. 2012; 57: 782– 788.
    1. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, Third edition (2010). October, 2010. Available at: . Accessed September 24, 2015.
    1. Hennings JM, Owashi T, Binder EB, et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients—findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res. 2009; 43: 215– 229.
    1. Katz MM, Meyers AL, Prakash A, et al. Early symptom change prediction of remission in depression treatment. Psychopharmacol Bull. 2009; 42: 94– 107.
    1. Stassen H, Anghelescu IG, Angst J, et al. Predicting response to psychopharmacological treatment: survey of recent results. Pharmacopsychiatry. 2011; 44: 263– 272.
    1. Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009; 70: 344– 353.
    1. van Calker D, Zobel I, Dykierek P, et al. Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy. J Affect Disord. 2009; 114: 243– 253.
    1. Gorwood P, Bayle F, Vaiva G, et al. Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis. Eur Psychiatry. 2013; 28: 362– 371.
    1. Wang G, McIntyre A, Earley WR, et al. A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2014; 10: 201– 216.
    1. Cutler AJ, Montgomery SA, Feifel D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 2009; 70: 526– 539.
    1. Weisler R, Joyce M, McGill L, et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 2009; 14: 299– 313.
    1. Bortnick B, El-Khalili N, Banov M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord. 2011; 128: 83– 94.
    1. Katila H, Mezhebovsky I, Mulroy A, et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry. 2013; 21: 769– 784.
    1. Liebowitz M, Lam RW, Lepola U, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety. 2010; 27: 964– 976.
    1. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009; 70: 540– 549.
    1. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010; 13: 917– 932.
    1. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382– 389.
    1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: 56– 62.
    1. National Institute of Mental Health. CGI Clinical Global Impressions. In: Guy W, Bonato RR, eds. Manual for the ECDEU Assessment Battery. 2. Rev Ed Chevy Chase, MD: US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976; 217– 222.
    1. Bonett DG, Price RM. Statistical inference for generalized yule coefficients in 2 × 2 contingency tables. Sociol Methods Res. 2007; 35: 429– 446.
    1. Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol. 1993; 3: 127– 135.
    1. Katz MM, Houston JP, Brannan S, et al. A multivantaged behavioural method for measuring onset and sequence of the clinical actions of antidepressants. Am Int J Neuropsychopharmacol. 2004; 7: 471– 479.
    1. Muzina DJ, Chambers JS, Camacho TA, et al. Adjunctive aripiprazole for depression: predictive value of early assessment. Am J Manag Care. 2011; 17: 793– 801.
    1. Cha DS, McIntyre RS. Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother. 2012; 13: 1587– 1598.
    1. Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med. 2010; 122: 39– 48.
    1. Trivedi MH. Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. J Clin Psychiatry. 2009; 70(suppl 6): 26– 31.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit